Your browser doesn't support javascript.
loading
COVID-19 in unvaccinated patients with inborn errors of immunity-polish experience.
Koltan, Sylwia; Zietkiewicz, Marcin; Grzesk, Elzbieta; Becht, Rafal; Berdej-Szczot, Elzbieta; Cienkusz, Magdalena; Ewertowska, Marlena; Heropolitanska-Pliszka, Edyta; Krysiak, Natalia; Lewandowicz-Uszynska, Aleksandra; Mach-Tomalska, Monika; Matyja-Bednarczyk, Aleksandra; Milchert, Marcin; Napiórkowska-Baran, Katarzyna; Pieniawska-Smiech, Karolina; Pituch-Noworolska, Anna; Renke, Joanna; Rolinski, Jacek; Rywczak, Iwona; Stelmach-Goldys, Agnieszka; Strach, Magdalena; Suchanek, Hanna; Sulicka-Grodzicka, Joanna; Szczawinska-Poplonyk, Aleksandra; Tokarski, Slawomir; Wiesik-Szewczyk, Ewa; Wolska-Kusnierz, Beata; Zeman, Krzysztof; Pac, Malgorzata.
Afiliação
  • Koltan S; Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
  • Zietkiewicz M; Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Medical University of Gdansk, Gdansk, Poland.
  • Grzesk E; Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
  • Becht R; Clinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Berdej-Szczot E; Department of Paediatric and Paediatric Endocrinology, Upper-Silesian Paediatric Health Center, Katowice, Poland.
  • Cienkusz M; Department of Paediatric Haematology and Oncology and Transplantology Medical University of Lublin, Lublin, Poland.
  • Ewertowska M; Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
  • Heropolitanska-Pliszka E; Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.
  • Krysiak N; Department of Pediatrics, Immunology and Nephrology, Institute of Polish Mother's Health Center, Lódz, Poland.
  • Lewandowicz-Uszynska A; 3rd Department and Clinic of Paediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Wroclaw, Poland.
  • Mach-Tomalska M; Department of Clinical Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland.
  • Matyja-Bednarczyk A; Department of Immunology, University Children's Hospital of Cracow, Cracow, Poland.
  • Milchert M; 2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
  • Napiórkowska-Baran K; Department of Internal Medicine Rheumatology Diabetology Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Pieniawska-Smiech K; Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
  • Pituch-Noworolska A; Department of Clinical Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland.
  • Renke J; Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.
  • Rolinski J; Department of Immunology, University Children's Hospital of Cracow, Cracow, Poland.
  • Rywczak I; Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
  • Stelmach-Goldys A; Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland.
  • Strach M; Department of Immunology, University Children's Hospital of Cracow, Cracow, Poland.
  • Suchanek H; Department of Hematology, Holycross Cancer Center, Kielce, Poland.
  • Sulicka-Grodzicka J; Department of Immunology, Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.
  • Szczawinska-Poplonyk A; Department of Rheumatology and Immunology, Jagiellonian University Collegium Medicum, Kraków, Poland.
  • Tokarski S; Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Medical University of Gdansk, Gdansk, Poland.
  • Wiesik-Szewczyk E; Department of Rheumatology and Immunology, Jagiellonian University Collegium Medicum, Kraków, Poland.
  • Wolska-Kusnierz B; Department of Pediatric Pneumonology, Allergy and Clinical Immunology, Institute of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland.
  • Zeman K; Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.
  • Pac M; Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine, Warsaw, Poland.
Front Immunol ; 13: 953700, 2022.
Article em En | MEDLINE | ID: mdl-36211407
At the beginning of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, patients with inborn errors of immunity (IEI) appeared to be particularly vulnerable to a severe course of the disease. It quickly turned out that only some IEI groups are associated with a high risk of severe infection. However, data on the course of Coronavirus Disease 2019 (COVID-19) in patients with IEI are still insufficient, especially in children; hence, further analyses are required. The retrospective study included 155 unvaccinated people with IEI: 105 children and 50 adults (67.7% and 32.3%, respectively). Male patients dominated in the study group (94 people, 60.6%). At least two comorbidities were found in 50 patients (32.3%), significantly more often in adults (56% vs. 21%). Adult patients presented significantly more COVID-19 symptoms. Asymptomatic and mildly symptomatic course of COVID-19 was demonstrated in 74.8% of the entire group, significantly more often in children (88.6% vs. 46%). Moderate and severe courses dominated in adults (54% vs. 11.4%). Systemic antibiotic therapy was used the most frequently, especially in adults (60% vs. 14.3%). COVID-19-specific therapy was used almost exclusively in adults. In the whole group, complications occurred in 14.2% of patients, significantly more often in adults (30% vs. 6.7%). In the pediatric group, there were two cases (1.9%) of multisystem inflammatory syndrome in children. Deaths were reported only in the adult population and accounted for 3.9% of the entire study group. The death rate for all adults was 12%, 15.4% for adults diagnosed with common variable immunodeficiency, 12.5% for those with X-linked agammaglobulinemia, and 21.4% for patients with comorbidity. The results of our study imply that vaccinations against COVID-19 should be recommended both for children and adults with IEI. Postexposure prophylaxis and early antiviral and anti-SARS-CoV-2 antibody-based therapies should be considered in adults with IEI, especially in those with severe humoral immune deficiencies and comorbidity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Child / Humans / Male País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Child / Humans / Male País como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article